TuHURA Biosciences, Inc. (HURA) Stock Analysis

TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers

Mon, June 15, 2026 at 11:45 AM UTC 3 min read

TuHURA Biosciences has submitted an Investigational New Drug (IND) application for TBS-2025, a VISTA-inhibiting antibody aimed at treating molecularly defined subsets of acute myeloid leukemia (AML) and other blood-related cancers. This development is significant for investors as it marks a critical step in advancing their clinical pipeline, potentially positioning the company for future partnerships and revenue opportunities in the oncology market. Positive outcomes from the evaluation could enhance investor confidence and drive stock performance.

Read full article →

TuHURA Biosciences, Inc.'s (NASDAQ:HURA) Shift From Loss To Profit

Thu, April 2, 2026 at 10:13 AM UTC 4 min read

TuHURA Biosciences, Inc. (NASDAQ:HURA) has reported a shift from a loss to profitability, marking a significant milestone for the company. This transition is crucial for investors as it indicates improved operational efficiency and potential for future growth, enhancing shareholder confidence. The positive financial performance may attract new investors and support the stock's upward momentum in the market.

Read full article →